Clinical trials: Malaria Vaccines, active
Malaria
Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Background: Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in places were malaria is common, such as Africa but can…
- Trial name
- NCT02639299
- Where
- United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria Vivax
Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
- Trial name
- Vivaxin-001 (NCT07172724)
- Testing
- Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory
- Where
- Brazil
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
This is a Phase Ib age de-escalation, dose escalation, open-label study to assess the safety and immunogenicity of the multi-stage malaria vaccine candidate R21 plus RH5.1 and/or R78C in Matrix-M in adults aged 18-35 years and…
- Trial name
- VAC093 (NCT06958198)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Plasmodium Vivax Malaria, Plasmodium Vivax Infection
Phase IIa/b Trial of PvCS/Montanide ISA-51 Malaria Vaccine in Adults in Chocó, Colombia
This clinical study will evaluate an investigational malaria vaccine called PvCS/Montanide ISA-51 to determine whether it is safe and whether it can protect adults from infection with Plasmodium vivax, one of the main parasites…
- Conditions
- Plasmodium Vivax Malaria, Plasmodium Vivax Infection, Malaria Prevention
- Trial name
- PvCS/M51 (NCT07373301)
- Testing
- PvCS/Montanide ISA-51 VG Vaccine
- Where
- Colombia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Plasmodium Falciparum Malaria
Mass Vaccine and Drug Administration, Bangladesh
This is an open i.e. not blinded, cluster-randomised, controlled intervention study. The study will use a factorial design to estimate the protective effectiveness of mass drug administrations, mass vaccinations, combined mass…
- Trial name
- MVDA (NCT06068530)
- Testing
- DHA/piperaquine and a SLD-PQ, Study vaccine R21/Matrix-M™
- Where
- 2 sites in Bangladesh
- Volunteers
- 10,000 people
- Sponsor
- University of Oxford
Malaria
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
This is a single centre, randomized, placebo-controlled phase 1/2 study comparing two malaria vaccine candidates. The first vaccine candidate PfSPZ-CVac (Plasmodium falciparum sporozoites (PfSPZ) challenge administered with a…
- Trial name
- NCT05441410
- Testing
- Pyronaridine Tetraphosphate, Artesunate Drug Combination, PfSPZ Challenge (NF54), MVA ME-TRAP
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Vaccination
Testing a Biometric Identification System to Improve Malaria Vaccine Completion
Receiving all four doses of the malaria vaccine can significantly protect children against malaria illness, hospitalization, and death. However, in Ghana, only 46% of children complete the full vaccination sequence.
- Trial name
- NCT07261280
- Testing
- HEALTH FACILITY INTERVENTION, INDIVIDUAL INTERVENTION
- Where
- Ghana
- Volunteers
- 4,715 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Iron Deficiencies
The Effects of Iron Treatment on Vaccine Immunogenicity in Kenyan Infants With Iron Deficiency
Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
- Trial name
- NCT06816524
- Testing
- Iron syrup, Multivitamin syrup, R21-Matrix/M Vaccine (malaria vaccine)
- Where
- Kenya
- Volunteers
- 324 people
- Sponsor
- Nicole Stoffel
Healthy Women of Child Bearing Potential
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
This will be a double-blind, individually randomised trial, to assess the safety, tolerability, immunogenicity, and protective efficacy of two and three doses of the R21/Matrix-M1 malaria vaccine or placebo given at 4 week…
- Trial name
- NCT06080243
- Testing
- R21/Matrix-M1, Saline and R21/Matrix-M1, Sterile isotonic (0.9%) normal saline
- Where
- Mali
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria (Plasmodium Falciparum)
Dose Finding Trial of R21/Matrix-M in School Children
This trial is a double-blind, randomised, trial recruiting participants from the R21 phase IIb trial (VAC 076) which took place between May 2019 and July 2023 in Nanoro, Burkina Faso.
- Trial name
- NCT07074665
- Testing
- 5µg R21/50µg Matrix-M, 10µg R21/50µg Matrix-M
- Where
- Burkina Faso
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria,Falciparum
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
This is a Phase IIb randomised controlled trial of the safety, immunogenicity and efficacy of the malaria vaccine candidates R78C with Matrix-M™, and the combination of RH5.1 and R21 with Matrix-M™, in children aged 5-36 months…
- Trial name
- VAC087 (NCT07183371)
- Testing
- R21, RH5.1, R78C
- Where
- Burkina Faso
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria Vaccine
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21…
- Trial name
- IMVACS (NCT06860178)
- Testing
- Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Epicentre
Malaria Vaccines, Malaria (Plasmodium Falciparum)
Infant Malaria Vaccine Schedule Optimization
The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.
- Trial name
- NCT06879327
- Testing
- R21 Matrix-M (R21/MM) Malaria Vaccine, Hexavalent Vaccine, Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- 2 sites in Burkina Faso
- Volunteers
- 975 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria (Plasmodium Falciparum)
Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a randomized, double-blind, placebo-controlled, Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine (Sanaria® PfSPZ-LARC2 Vaccine)…
- Trial name
- BFSPZL3 (NCT07730177)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline
- Where
- Burkina Faso
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria (Plasmodium Falciparum)
Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults
This is a phase 2 clinical trial of a Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) vaccine (Sanaria® PfSPZ-LARC2 Vaccine) that will assess field efficacy in Africa.
- Trial name
- BFSPZL2 (NCT07385287)
- Testing
- Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)
- Where
- Burkina Faso
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Invasive Non-Typhoidal Salmonella Disease, Malaria
Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease
The goal of this observational study is to learn about the impact of malaria vaccination on the risk of invasive non-typhoidal Salmonella disease in children below the age of 5.
- Conditions
- Invasive Non-Typhoidal Salmonella Disease, Malaria, Malaria Vaccine
- Trial name
- VINS (NCT07416461)
- Testing
- R21/Matrix-M malaria vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 10,000 people
- Sponsor
- International Vaccine Institute
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Malaria, Falciparum
Perennial Malaria Chemoprevention in the Malaria Vaccine Era
Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and…
- Trial name
- PMC-VAC (NCT07322068)
- Testing
- Sulfadoxine pyrimethamine + Amodiaquine, Dihydroartemisinin Piperaquine
- Where
- Uganda
- Volunteers
- 1,290 people, healthy volunteers welcome
- Sponsor
- Stanford University